MyFinsight
Home
Blog
About
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,809,406
Unit: Dollar
Positive Cash Flow Breakdown
Effect of exchange rate on chang...
Depreciation and amortization ex...
Accounts payable
Share-based compensation
Negative Cash Flow Breakdown
Accrued expenses and other curre...
Prepaid expenses
Net (loss) income
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net (loss) income
-505,063
1,864,092
-9,906,504
-369,632
Share-based compensation
70,286
93,701
111,277
163,772
Depreciation and amortization expense
165,695
165,789
165,792
662,890
Non-cash rent expense
0
-87,269
-27,393
-114,363
Change in fair value of accompanying warrant liability
-255,409
-5,379,434
4,390,726
-956,340
Change in fair value of contingent consideration
-127,098
-5,975
-12,763
716,654
Effect of foreign currency remeasurement
496,692
-224,289
-32,644
-242,348
Accounts receivable, non-trade
495,432
1,108,150
-10,190
-114,936
Prepaid expenses
584,959
-195,365
-517,874
453,058
Accounts payable
106,476
-850,019
216,359
-917,663
Accrued expenses and other current liabilities
-1,179,475
-1,602,739
718,261
1,486,656
Operating lease liabilities
0
-85,210
-31,104
-123,304
Deferred tax liability
-34,794
-34,793
-34,793
-468,427
Contingent consideration
-
-
-
-133,080
Other non-current liabilities
-
-
-
-2,886
Net cash (used in) provided by operating activities
-3,336,465
-6,435,815
-3,794,648
77,229
Proceeds from the sale of equity, net of issuance costs
0
14,662,268
3,253,615
1,528,276
Net cash provided by financing activities
0
14,662,268
3,253,615
1,528,276
Effect of exchange rate on changes in cash, cash equivalents, and restricted cash
527,059
295,406
-19,455
-3,750
Net increase in cash, cash equivalents, and restricted cash
-2,809,406
8,521,859
-560,488
1,601,755
Cash, cash equivalents, and restricted cash, beginning of period
13,728,202
13,728,202
14,288,690
12,686,935
Cash, cash equivalents, and restricted cash, end of period
19,440,655
22,250,061
13,728,202
14,288,690
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Effect of exchange rate
on changes in cash,...
$527,059
Net increase in
cash, cash...
-$2,809,406
Canceled cashflow
$527,059
Depreciation and
amortization expense
$165,695
Accounts payable
$106,476
Share-based compensation
$70,286
Net cash (used in)
provided by operating...
-$3,336,465
Canceled cashflow
$342,457
Accrued expenses and
other current...
-$1,179,475
Prepaid expenses
$584,959
Net (loss) income
-$505,063
Effect of foreign
currency remeasurement
$496,692
Accounts receivable,
non-trade
$495,432
Change in fair value of
accompanying warrant...
-$255,409
Change in fair value of
contingent consideration
-$127,098
Deferred tax liability
-$34,794
Buy us a coffee